Medchemfarma has got access to funds through the support of the Ministerio de Ciencia, Innovación y Universidades, Next Generation EU funds and from the Recovery, Transformation and Resilience Plan, (call 2022) to execute the following Project: Discovery and preclinical development of new compounds as HPK1 inhibitors for cancer treatment (HPK1-inhib) (CPP2022-009716).
